OncoMatch/Clinical Trials/NCT03258320
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Is NCT03258320 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin for prostate cancer patients.
Treatment: Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin — Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C (AJCC TNM (2016, 8th Edition))
Excluded: Stage IV
A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition)
Performance status
WHO 0–1
Prior therapy
Cannot have received: cancer chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify